- Characterization of highly active mutational signatures in tumors from a large Chinese population 1 2 Aaron Chevalier^{1,2*}, Tao Guo^{1,3*}, Natasha Q. Gurevich^{1,2*}, Jingwen Xu^{1,3}, 3 Masanao Yajima³, Joshua D. Campbell^{1,2} 4 5 6 1. Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, 7 Boston, Massachusetts, 8 2. Bioinformatics Program, Boston University, Boston, Massachusetts. 3. Department of Mathematics & Statistics, Boston University, Boston, Massachusetts. 9 * These authors contributed equally to this work. 10 11 12 **Corresponding author:** 13 Joshua D. Campbell 14 Email: camp@bu.edu 72 E Concord St 15 16 Boston, MA 02118 17 18 19 20 Abstract The majority of mutational signatures have been characterized in tumors from Western countries and the degree 21 to which mutational signatures are similar or different in Eastern populations has not been fully explored. We 22 23 leveraged a large-scale clinical sequencing cohort of tumors from a Chinese population containing 25 tumor 24 types and found that the highly active mutational signatures were similar to those previously characterized^{1,2}. The aristolochic acid signature SBS22 was observed in four soft tissue sarcomas and the POLE-associated 25 signature SBS10 was observed in a gallbladder carcinoma. In lung adenocarcinoma, the polycyclic aromatic 26 hydrocarbon (PAH) signature SBS4 was significantly higher in males compared to females but not associated 27 with smoking status. The UV-associated signature SBS7 was significantly lower in cutaneous melanomas from 28 the Chinese population compared to a similar American cohort. Overall, these results add to our understanding 29 of the mutational processes that contribute to tumors from the Chinese population. 30 31
- 32
- 33
- 34
- 35
- 36
- 37

38 Main

A variety of exogenous exposures or endogenous biological processes can contribute to the overall mutational 39 load observed in human tumors^{1,3,4}. Many different mutational patterns, or "mutational signatures", have been 40 41 identified across different tumor types^{3,5–9} which can provide a record of environmental exposure or clues about the etiology of carcinogenesis¹⁰. The majority of mutational signature characterization has been performed using 42 43 tumors from Western populations due to the availability of sequencing data in these regions from large-scale 44 atlases such as The Cancer Genome Atlas (TCGA)¹¹ and the International Cancer Genome Consortium (ICGC)¹². While cancer incidence and mortality can vary across regions and countries¹³, the degree to which 45 mutational signatures are similar or different between populations remains an open area of exploration. 46 Exposures to certain carcinogens and their corresponding mutational signatures have been characterized in 47 Eastern populations. For example, aristolochic acid is found in herbal medicines used in Asian populations and 48 can cause the single-base substitution (SBS) signature SBS22 in hepatocellular carcinomas (HCCs)¹⁴. Similarly, 49 exposure to aflatoxin B1 produced by molds growing on food can cause SBS24 in HCCs¹⁵. 50

51

52 Previously, a large-scale cohort of tumors from the Chinese population was profiled with a targeted DNA sequencing panel developed by OrigiMed (OM cohort)¹⁶. This work compared the frequency of driver genes, 53 tumor mutational burden (TMB), dene fusions, and clinically actionable alterations between tumors from Chinese 54 and American populations. We further leveraged this cohort to characterize the landscape of highly active 55 mutational signatures across a large spectrum of tumor types in the Chinese population. 2,115 tumors with at 56 least 10 mutations from 25 tumor types were utilized for mutational signature analysis. We first performed de 57 novo deconvolution with Non-Negative Matrix Factorization (NMF) using the SigProfiler package¹⁷ and identified 58 six mutational signatures (Supplementary Figure 1, Supplementary Table 1, Supplementary Table 2). All 59 60 signatures were highly correlated with previously defined signatures in the COSMIC database, indicating that no 61 new highly active mutational processes were present in this cohort. The discovered signatures included those correlated with SBS1/6, SBS4, SBS10, SBS12/26, SBS2/13, and SBS22. 62

63

64 The limited number of mutations in the targeted sequencing data can hinder de novo mutational signature discovery. Therefore, we also predicted signature activity levels for existing COSMIC signatures using the 65 musicatk package¹⁸ (**Supplementary Table 3**). The landscape of activities for 16 signatures across tumor types 66 is shown in Figure 1 (Supplementary Table 4). Signatures related to endogenous biological processes included 67 68 the aging-related signature SBS1 and the clock-like signature SBS5 which were broadly detected across tumor types. The APOBEC-related signatures SBS2 and SBS13 were often observed together across a variety of 69 70 epithelial tumor types such as breast carcinoma, carcinoma of the uterine cervix, esophageal carcinoma, gall 71 bladder carcinoma, non-small cell lung cancer (NSCLC), and urothelial carcinoma. Several signatures related to 72 defective mismatch repair (MMR), microsatellite instability (MSI), or defective DNA polymerase activity were detected, including SBS6, SBS15, SBS20, SBS21, SBS26, SBS17, and SBS10. As previously observed in 73 Western cohorts, these signatures often co-occurred in the same samples^{1,2}. One or more of these signatures 74 75 were active in samples from many of the same tumor types observed in Western cohorts including bone sarcoma¹, colorectal carcinoma¹, intrahepatic and extrahepatic cholangiocarcinoma¹, gall bladder carcinoma¹⁹, 76 dastric cancer²⁰, head and neck carcinoma¹, kidney/renal cell carcinoma¹, ovarian carcinoma¹, pancreatic 77 cancer¹, small bowel carcinoma²¹, soft tissue sarcoma²², and uterine corpus endometrial carcinoma¹. We also 78 observed three gallbladder carcinomas with high levels of SBS6 as well as one sample with SBS10 (POLE). 79 which has not been previously observed for this cancer type^{23,24}. High levels of SBS17 were found in a small 80 number of tumors from breast carcinoma, colorectal carcinoma, extrahepatic cholangiocarcinoma, gastric 81 cancer, or liver/hepatocellular carcinoma. While this signature often co-occurred with other signatures, some 82 tumors contained only this signature. High levels of SBS10 related to defects in POLE were observed in 22 83 colorectal carcinomas and 3 uterine corpus endometrial carcinomas. 84

85

Several detected signatures are known to be caused by exposure to exogenous DNA damaging agents. SBS4 86 is caused by exposure to polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene in cigarette smoke²⁵ 87 88 and was observed in small cell lung cancers (SCLCs) and NSCLCs. SBS22 is caused by exposure to aristolochic acid and was detected in liver/hepatocellular carcinomas, intra and extrahepatic cholangiocarcinomas. 89 kidney/renal cell carcinomas, and urothelial carcinomas (Figure 2A). Interestingly, SBS22 was also detected in 90 four soft tissue sarcomas and one esophageal carcinoma, which has not been previously reported^{22,26} (Figure 91 2B). SBS24 reflecting aflatoxin B1 exposure was detected at high or moderate levels in 2 liver/hepatocellular 92 carcinomas similar to previous reports^{1,27}. This signature was also highly detected in 1 colorectal carcinoma and 93 1 gastric cancer raising the possibility that this exposure or something similar can induce mutations in more 94 tumor types than previously appreciated. SBS7 is caused by UV radiation exposure and was highly detected in 95 2 melanomas, 1 head & neck carcinoma, and 2 urothelial carcinomas. Lastly, SBS18 which is potentially due to 96 oxidative stress was detected in 1 colorectal carcinoma. 97

98

We next sought to directly compare the signature activity levels in this Chinese population to a similar clinical 99 cohort of tumors from an American population. Specifically, we leveraged a dataset generated at Memorial Sloan 100 Kettering (MSK) that was profiled with the IMPACT targeted sequencing panel. After mapping major tumor types 101 and tumor subtypes between cohorts, 13 groups with at least 5 samples in each cohort were compared 102 (Supplementary Table 5). For each signature, we first compared the proportion of samples with high activity of 103 that signature between cohorts using a Fisher's exact text. The only significant difference was that the American 104 cohort had a higher proportion of tumors with the UV signature SBS7 in soft tissue sarcoma compared to the 105 Chinese cohort (FDR < 0.05; Figure 3A; Supplementary Table 6). The MSK cohort did not have any tumors 106 with high SBS22 reflecting that aristolochic acid exposure is largely occurs in Eastern population. Next, we 107 108 compared the median activity of the proposal signature activities across cohorts. The majority of the proportional signature activities were not significantly different between cohorts after applying an FDR correction (Figure 3B: 109 Supplementary Table 7). The only exceptions were that SBS2 in breast carcinoma, SBS6 in colorectal 110 carcinoma, and SBS5 in hepatocellular carcinoma had significantly lower levels in the OM cohort compared to 111 the MSK cohort (Wilcoxon rank-sum test; FDR < 0.05). These results demonstrate that the major differences 112 between populations are due to exposure to specific mutagens and that the levels of other common signatures 113 are largely the same in tumors across Chinese and American populations despite the underlying heterogeneity 114 115 in clinical and regional characteristics.

116

SBS4 was highly prevalent across NSCLCs including lung adenocarcinomas (LUADs) and lung squamous cell 117 carcinomas (LUSCs) as well as in small cell lung cancer (SCLCs) as previously observed^{1,25,28,29} (Figure 1. 118 Figure 4A). In China, rates of cigarette smoking are much higher among males compared to females³⁰. We 119 observed similar trends in this cohort with a higher proportion of male in the smokers compared to the non-120 smokers (p < 2.2e-16; Fisher's exact text; Figure 4B), Furthermore, LUADs from female non-smokers in Asian 121 populations tend to be driven by alterations in EGFR³¹. Similarly, in this cohort we observed a higher proportion 122 of tumors with EGFR mutations in females compared to males in both the smokers (p = 0.0061) as well as the 123 non-smokers (p = 0.0004; Figure 4B). In Western cohorts, SBS4 activity is strongly associated with smoking 124 status in LUAD³². Surprisingly in this Chinese cohort, the SBS4 signature was not associated with smoking status 125 but instead was strongly associated with sex (Figure 4C). Specifically, the level of SBS4 activity was significantly 126 higher in males compared to females within smokers (p = 0.00398) and even more so within non-smokers (p = 0.00398) 127 4.37e-07). SBS4 was not significantly different between smokers and non-smokers in males or between smokers 128 and non-smokers in females (p > 0.05) indicating that the association with sex is not just due to the differences 129 in the prevalence of smoking between men and women. When applying a multivariate linear model to a subset 130 of LUADs with complete clinical information (n=271), SBS4 activity was significantly higher in males compared 131

to females (p = 1.48e-07), decreasing with age (p = 0.0.0013), lower in tumors with EGFR mutations (p = 1.48e-07) 132 0.0072), and lower in metastatic versus primary samples (p = 0.0004). SBS4 activity was not significantly 133 associated with tumor purity, stage, or smoking status (p > 0.01; Figure 4D). No associations were found 134 between SBS4 activity and these variables in LUSC or SCLC (p > 0.01; Supplementary Figure 2) demonstrating 135 that this phenomenon is specific to LUAD. While inaccurate self-reported smoking status may be a factor, these 136 137 findings may suggest that factors other than smoking status are contributing to SBS4 mutations in males from China. Other possible factors affecting SBS4 mutations in males may include a higher daily usage of cigarettes 138 or a higher exposure to air pollution and ambient particulate matter compared to women^{33,34}. Additional cohorts 139 of LUADs with detailed smoking and exposure history will likely be needed to further understand the causes of 140 141 this association.

142

In the OM cohort, only 7 of 54 melanomas had greater than 10 mutations (13%) which is significantly less than 143 the MSK cohort in which 145 of 358 (41%) of the melanomas had greater than 10 mutations (p = 6.0e-05; Fisher's 144 exact text), SBS7 was only highly detected in 2 of the 7 melanomas in the OM cohort (Figure 5A), Asian 145 populations have higher rates of acral and mucosal melanomas whereas Western populations have higher rates 146 of cutaneous melanoma^{35,36}. Acral and mucosal subtypes often have lower mutation rates and are less driven 147 by UV-induced DNA damage compared to cutaneous melanomas³⁷. To understand differences between 148 populations specifically in cutaneous melanoma, we expanded the analysis to examine the mutational profiles 149 of all cutaneous melanomas across both cohorts (including tumors with less than 10 mutations which were 150 excluded in the mutational signature analysis). Cutaneous melanomas from the OM cohort (n=26) had 151 significantly lower SBS mutations per megabase (Mb) than cutaneous melanomas from the MSK cohort (n = 152 191: p = 1.5e-13; Figure 5B). They also had lower frequencies of any C>T mutations (p = 1.1e-7; Figure 5C) 153 and C>T mutations at the TCA, CCC, and TCT trinucleotide contexts, which are the most common contexts in 154 155 the UV-associated signature SBS7 (p = 1.1e-5; Figure 5D). These findings corroborate the recent work showing that the number of UV-associated mutations in normal skin is lower in Asian populations compared to Western 156 populations despite Asian populations having higher levels of exposure to UV radiation³⁸. Additionally, lower 157 response rates to immune checkpoint inhibitors have been observed in melanomas from the Chinese population 158 compared to Western populations³⁹ which could be a result of the lower tumor mutation burden (TMB)⁴⁰. Our 159 data suggests that the lower prevalence of UV-associated mutations is a major contributor to the lower overall 160 TMB in Chinese cutaneous melanomas. 161

162

Overall, this analysis provides an overview into the mutational signatures that are highly active in a large Chinese 163 population. One limitation of this study is that the OM cohort was profiled with a targeted sequencing panel which 164 has a lower number of mutations detected per tumor. Having lower counts can hinder detection of signatures 165 that tend to have lower activity levels. For example, we were not able to confidently detect signature SBS3 which 166 denotes homologous repair deficiency (HRD) caused by loss of BRCA1/2. SBS3 has been previously 167 characterized in breast cancers from Chinese and Korean populations^{41,42}. Despite this limitation, we were able 168 to detect signatures that are highly active in these tumors (i.e. signatures that produce enough mutations to be 169 detected with a limited targeted sequencing panel) and characterize novel associations specific to this Chinese 170 171 population.

- 172
- 173
- 174

175 Online Methods

176

Cohort. The full details of the patient consent, clinical characteristics, biospecimen processing, and DNA 177 sequencing have been previously described¹⁶. Briefly, tumors from 25 tumor types were profiled with a DNA 178 sequencing panel targeting 450 genes, TERT promoter mutations, and 39 introns in a Clinical Laboratory 179 180 Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited laboratory 181 by the Chinese-based company OrigiMed. The mutations and clinical data were retrieved from the cBioPortal (https://www.cbioportal.org/study/summary?id=pan_origimed_2020). Each tumor has a major cancer type and a 182 more specific detailed cancer type. For most tumors, we used the major cancer type label. Given the high 183 numbers of Non-Small Cell Lung Cancers (NSCLCs) in this dataset, we divided this group into Lung 184 Adenocarcinomas (LUADs), Lung Squamous Cell Carcinomas (LUSCs), and "NSCLC - Other" which contained 185 the subcategories of "Lung Adenosquamous Carcinoma", "Large Cell Lung Carcinoma", and "Non-Small Cell 186 187 Lung Cancer Other".

188

Signature discovery and prediction. Single base substitutions (SBSs) were extracted in each tumor to produce 189 a count table using the musicatk R package v1.91¹⁸. Mutational signature discovery and prediction was limited 190 to 2.115 tumors from 25 major tumor types that had at least 10 single base substitutions. Mutational signatures 191 were first discovered de novo using NMF from the SigProfiler package v1.1.4¹⁷ setting the reference genome to 192 GRch38. The number of signatures predicted was varied from one to eight and the optimal number of six was 193 194 chosen based on the maximal difference between the mean sample cosine distance and average stability metrics. Discovered signatures were compared to those from the COSMIC V2 database using cosine similarity. 195 Next, the activity of all COSMIC V2 signatures were predicted using the "auto predict grid" function in the 196 musicatk package with the "algorithm" parameter set to "Ida posterior" and the "sample annotation" parameter 197 198 set to the tumor type¹⁸. Initially, 25 signatures were detected with this method. We manually reviewed each signature according to criteria set in the PanCancer Analysis of Whole-Genomes (PCAWG) mutational signature 199 working group². Specifically, we examined the mutation counts from individual tumors with high predicted 200 activities of each signature. If no individual tumors displayed a mutational pattern that was predominantly 201 202 correlated with the signature, then this signature was excluded from the final signature set. The final signature activities were predicted using the "predict exposure" function with the "algorithm" parameter set to "Ida" and 203 specifying sixteen SBS signatures that passed inspection including 1, 2, 4, 5, 6, 7, 10, 13, 15, 17, 18, 20, 21, 22, 204 205 24, and 26. A signature was considered highly active in an individual tumor if it contained at least 10 estimated counts in that tumor. Proportional signature activities were calculated by dividing each signature activity within a 206 207 tumor by the total number of estimated signature activity counts from that tumor.

208

209 Comparison to Western cohorts. Mutations for the MSK cohort were downloaded from cBioPortal 210 (https://www.cbioportal.org/study/summary?id=msk_impact_2017). SBSs were extracted from each tumor using the musicatk package and samples with at least 10 mutations were retained for the analysis. The same 211 212 signatures that were detected in the OM cohort were predicted in the MSK cohort using the "predict exposure" function with the "algorithm" parameter set to "Ida". Tumor types were mapped between cohorts using either the 213 214 major or more detailed cancer type label (Supplementary Table 3). The medial level of proportional activity for 215 each signature in a tumor type was compared across cohorts using a Wilcoxon rank-sum test followed by correction for multiple hypothesis testing using the False Discovery Rate (FDR). The frequencies of tumors with 216 detected signature activity were compared across cohorts using the Fisher's exact test followed by and FDR 217 correction. Only tumor types with at least 5 tumors in both cohorts were including in the analysis. For both 218 comparisons, only signatures with a median level of 0.01 across all samples from both cohorts were included in 219 the analysis. 220

222 Determining association to other clinical or genomic variables. The Wilcoxon rank-sum test was used to assess differences in normalized signature activities between two groups. The association between SBS4 223 224 activity and covariates was also assessed using multivariate linear regression within each lung tumor type. SBS4 225 activity was log transformed after adding a pseudocount of 1 and treated as the dependent variable. Independent 226 variables included age at diagnosis, sex, smoking status, stage according to the American Joint Committee on 227 Cancer (AJCC), tumor purity, EGFR mutation status, and sample type (primary or metastasis). Samples with 228 "Unknown" status for any variable were excluded from the regression and any variable that did not have more 229 than one category within a cancer type was excluded from the regression for that cancer type.

230

231 **Code availability.** All code for the analysis is available on GitHub at https://github.com/campbio-232 manuscripts/Chinese_Mutsigs.

233 Acknowledgements

This work was funded by the National Cancer Institute (NCI) Informatics Technology for Cancer Research (ITCR)
1U01CA253500 (J.D. Campbell and M. Yajima). We thank Drs. Kai Wang and Xiaoliang Shi for helpful insights
about the OrigiMed dataset.

238 References

- Alexandrov, L. B. *et al.* The repertoire of mutational signatures in human cancer. *Nature* **578**, 94–101 (2020).
- ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole
 genomes. *Nature* 578, 82–93 (2020).
- 3. Alexandrov, L. B. *et al.* Signatures of mutational processes in human cancer. *Nature* **500**, 415–21 (2013).
- Lawrence, M. S. *et al.* Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* **499**, 214–218 (2013).
- 5. Alexandrov, L. B., Nik-Zainal, S., Siu, H. C., Leung, S. Y. & Stratton, M. R. A mutational signature in gastric cancer suggests therapeutic strategies. *Nat Commun* **6**, 8683 (2015).
- 6. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. *Cell Rep* **3**, 246–59 (2013).
- Kim, J. *et al.* Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial
 tumors. *Nat Genet* 48, 600–606 (2016).
- 8. Morganella, S. *et al.* The topography of mutational processes in breast cancer genomes. *Nat Commun* **7**, 11383 (2016).
- Roberts, S. A. *et al.* An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. *Nat Genet* 45, 970–976 (2013).
- 10. Nik-Zainal, S. *et al.* The genome as a record of environmental exposure. *Mutagenesis* **30**, 763–70 (2015).
- 11. Weinstein, J. N. *et al.* The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet* 45, 1113–1120 (2013).
- 12. Zhang, J. *et al.* The International Cancer Genome Consortium Data Portal. *Nat Biotechnol* **37**, 367–369
 (2019).
- 13. Lin, L. *et al.* Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and
 trends analysis of the global cancer burden, 1990-2019. *J Hematol Oncol* 14, 197 (2021).
- 14. Kaya, N. A. *et al.* Genome instability is associated with ethnic differences between Asians and Europeans
 in hepatocellular carcinoma. *Theranostics* **12**, 4703–4717 (2022).
- 15. Huang, M. N. *et al.* Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors.
 Genome Res 27, 1475–1486 (2017).
- Wu, L. *et al.* Landscape of somatic alterations in large-scale solid tumors from an Asian population. *Nat Commun* 13, 4264 (2022).
- 17. Islam, S. M. A. *et al.* Uncovering novel mutational signatures by de novo extraction with
 SigProfilerExtractor. *Cell genomics* 2, None (2022).
- Chevalier, A. *et al.* The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the
 Discovery, Prediction, and Exploration of Mutational Signatures. *Cancer Res* 81, 5813–5817 (2021).
- 19. Guo, L. *et al.* Genomic mutation characteristics and prognosis of biliary tract cancer. *Am J Transl Res* 14, 4990–5002 (2022).
- 20. Pužar Dominkuš, P. & Hudler, P. Mutational Signatures in Gastric Cancer and Their Clinical Implications.
 Cancers (Basel) 15, (2023).
- 277 21. Hänninen, U. A. *et al.* Exome-wide somatic mutation characterization of small bowel adenocarcinoma.
- 278 *PLoS Genet* **14**, e1007200 (2018).

- 22. Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca &
 Cancer Genome Atlas Research Network. Comprehensive and Integrated Genomic Characterization of
 Adult Soft Tissue Sarcomas. *Cell* **171**, 950-965.e28 (2017).
- 282 23. Nepal, C. *et al.* Integrative molecular characterisation of gallbladder cancer reveals micro-environment-283 associated subtypes. *J Hepatol* **74**, 1132–1144 (2021).
- 24. Kang, M. *et al.* Gallbladder adenocarcinomas undergo subclonal diversification and selection from
 precancerous lesions to metastatic tumors. *Elife* 11, (2022).
- 25. Alexandrov, L. B. *et al.* Mutational signatures associated with tobacco smoking in human cancer. *Science* 354, 618–622 (2016).
- 26. Lim, A. H. *et al.* Rare Occurrence of Aristolochic Acid Mutational Signatures in Oro-Gastrointestinal Tract
 Cancers. *Cancers (Basel)* 14, (2022).
- 27. Damrauer, J. S. *et al.* Genomic characterization of rare molecular subclasses of hepatocellular carcinoma.
 Commun Biol 4, 1150 (2021).
- 28. van den Heuvel, G. R. M. *et al.* Mutational signature analysis in non-small cell lung cancer patients with a
 high tumor mutational burden. *Respir Res* 22, 302 (2021).
- 29. Wang, H. *et al.* Molecular subtyping of small-cell lung cancer based on mutational signatures with different
 genomic features and therapeutic strategies. *Cancer Sci* **114**, 665–679 (2023).
- 30. Zhang, M. *et al.* Trends in smoking prevalence in urban and rural China, 2007 to 2018: Findings from 5
 consecutive nationally representative cross-sectional surveys. *PLoS Med* **19**, e1004064 (2022).
- 31. Ha, S. Y. *et al.* Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often
 involving EGFR. *Oncotarget* 6, 5465–74 (2015).
- 32. Campbell, J. D. *et al.* Distinct patterns of somatic genome alterations in lung adenocarcinomas and
 squamous cell carcinomas. *Nat Genet* 48, 607–16 (2016).
- 33. Yin, P. *et al.* The effect of air pollution on deaths, disease burden, and life expectancy across China and
 its provinces, 1990-2017: an analysis for the Global Burden of Disease Study 2017. *Lancet Planet Health*4, e386–e398 (2020).
- 34. Liu, S. *et al.* Prevalence and patterns of tobacco smoking among Chinese adult men and women: findings
 of the 2010 national smoking survey. *J Epidemiol Community Health (1978)* **71**, 154–161 (2017).
- 35. Lv, J., Dai, B., Kong, Y., Shen, X. & Kong, J. Acral Melanoma in Chinese: A Clinicopathological and
 Prognostic Study of 142 cases. *Sci Rep* 6, 31432 (2016).
- 36. Chang, J. W.-C. *et al.* Malignant melanoma in Taiwan: a prognostic study of 181 cases. *Melanoma Res*14, 537–41 (2004).
- 37. Rose, A. A. N. *et al.* Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. *J Immunother Cancer* **9**, (2021).
- 38. King, C. *et al.* Somatic mutations in facial skin from countries of contrasting skin cancer risk. *Nat Genet*55, 1440–1447 (2023).
- 39. Si, L. *et al.* A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With
 Advanced or Metastatic Melanoma (KEYNOTE-151). *Transl Oncol* **12**, 828–835 (2019).
- 40. Huang, F. *et al.* Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets
 and prognostic biomarkers for immunotherapy. *Sci Rep* 12, 9559 (2022).
- 41. Jiang, Y.-Z. *et al.* Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes
 and Treatment Strategies. *Cancer Cell* **35**, 428-440.e5 (2019).
- 42. Pan, J.-W. *et al.* The molecular landscape of Asian breast cancers reveals clinically relevant populationspecific differences. *Nat Commun* **11**, 6433 (2020).
- 323
- 324

325 Figures





327

Figure 1. The landscape of highly active mutational signatures in a large Chinese population. Sixteen mutational signatures were identified across 2,115 tumors from 25 tumor types. The size of the dot corresponds to the percentage of tumors within each tumor type that have detectable levels of the signature. Signatures with at least 10 counts were considered detected in an individual tumor. The color of the dot corresponds to the median activity of each signature within the detected samples per megabase (Mb).

- 333
- 334
- 335



336

Figure 2. Prevalence of aristolochic acid (SBS22) activity across tumor types. (A) SBS22 reflects exposure to aristolochic acid and was highly active in 32 liver/hepatocellular carcinomas, 6 intra or extrahepatic cholangiocarcinomas, 3 kidney renal cell carcinomas, and 5 urothelial carcinomas. This signature was also detected in 4 soft tissue sarcomas and 1 esophageal carcinoma which has not been reported in Western cohorts. Each bar represents the level of the estimated signature activities in each sample and samples are ordered by the level of SBS22. (B) Mutation counts for 2 example liver/hepatocellular carcinomas, 3 soft tissue sarcomas, and 1 esophageal carcinoma that predominantly contain the SBS22 signature.

- 344
- 345
- 346



Figure 3. Comparison of signature detection and activity levels across populations. (A) Signatures with at least 10 counts in a tumor were considered detected in that tumor. The frequencies of detected signatures were compared across Chinese (OM) and American (MSK) cohort using the Fisher's exact test with an FDR correction. Only tumor types with at least 5 tumors in each cohort were included. The majority of signature detection rates were not significantly different between cohorts with the exception of the UV-associated signature SBS7 which was found in a higher proportion of soft tissue sarcomas in the MSK cohort compared to the OM cohort. (B) The median levels of proportional signature activities were compared for matched tumor types between the Chinese (OM) and American (MSK) cohorts using a Wilcoxon rank-sum test with an FDR correction. The majority of signature activities were not significantly different between cohorts with the exception of the APOBEC SBS2 signature in breast carcinoma, the SBS6 signature in colorectal carcinoma, and the SBS5 signature in hepatocellular carcinoma.



368 369

370 Figure 4. SBS4 activity associated with sex but not smoking status in lung adenocarcinoma. (A) SBS4 activity was predominantly observed in lung cancers including lung adenocarcinoma (LUAD), lung squamous 371 372 cell carcinoma (LUSC), and small cell lung cancer (SCLC). Each stacked bar represents the estimated activity 373 levels of each signature in each tumor. Signatures with no estimated activity in these tumor types were excluded. 374 (B) The relationship between smoking status, sex, and EGFR mutation status is shown for a subset of LUADs 375 with complete clinical information (n=271). A higher proportion of males were observed in smokers compared to 376 non-smokers and a higher proportion of EGFR mutations were observed in females compared to males in both 377 smokers and non-smokers. (C) Using a Wilcoxon rank-sum test, SBS4 activity was significantly higher in males 378 compared to females in both smokers and non-smokers but was not significantly different between smokers and 379 nonsmokers within males or within females. (D) Using a multivariate linear model, SBS4 activity was associated 380 with sex, sample type (i.e. lower in metastasis compared to primary), EGFR mutation status, and age.



Figure 5. Decrease in UV-associated mutations in cutaneous melanomas from Chinese patients. (A) Barplot of signature activities for 7 melanomas in the OM cohort. (B) The total number of SBS mutations per megabase (Mb), (C) the fraction of C>T mutations, and (D) the fraction of C>T mutations at the T<u>C</u>A, C<u>C</u>C, or T<u>C</u>T trinucleotide contexts were significantly lower in cutaneous melanomas from the Chinese cohort compared to cutaneous melanomas from the American cohort.

- 388
- 389
- 390
- 391
- 392
- 393

394 **Supplementary Figures**





396

Supplementary Figure 1. Discovery of mutational signatures *de novo* using NMF. (A) NMF in the SigProfiler package was run to identify mutational signatures. The optimal number of signatures was determined to be six based on the maximal difference between the mean sample cosine distance and average stability metrics. (B) All discovered signatures were highly correlated with at least one known signature in the COSMIC database showing that no new highly active signatures could be identified in this cohort.





404

Supplementary Figure 2. Lack of associations between clinical variables and SBS4 activity in lung
squamous cell carcinoma (LUSC) and small cell lung cancer (SCLC). A multivariate linear model was used
to assess the relationship between SBS4 activity and clinical variables in (A) lung squamous cell carcinoma and
(B) small cell lung cancer. Only moderate associations were observed between SBS4 activity and Stage II or
Stage III-IV tumors in LUSC or *EGFR* mutations in SCLC (p < 0.05). No associations were observed between
smoking status and sex (p > 0.05).